CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
This Quarter Return
+30.48%
1 Year Return
-42.86%
3 Year Return
+319.33%
5 Year Return
+899.35%
10 Year Return
–
AUM
$1.86B
AUM Growth
+$1.86B
(+20%)
Cap. Flow
+$153M
Cap. Flow
% of AUM
8.22%
Top 10 Holdings %
Top 10 Hldgs %
55.49%
Holding
32
New
3
Increased
14
Reduced
5
Closed
3
Top Buys
| 1 |
Myriad Genetics
MYGN
|
$75.7M |
| 2 |
United Therapeutics
UTHR
|
$37.8M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$28.7M |
| 4 |
LMNX
Luminex Corp
LMNX
|
$28.2M |
| 5 |
Theravance Biopharma
TBPH
|
$23.9M |
Top Sells
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$50.8M |
| 2 |
SPPI
Spectrum Pharmaceuticals Inc
SPPI
|
$19M |
| 3 |
Verastem
VSTM
|
$14.6M |
| 4 |
CSII
Cardiovascular Systems, Inc.
CSII
|
$9.87M |
| 5 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
$5.62M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pacira BioSciences
PCRX
$1.2B
| $180M | 9.67% | 3,652,134 -101,700 | -3% | -$5M |
|
2
Travere Therapeutics
TVTX
$1.56B
| $112M | 6.05% | 3,914,182 +70,811 | +2% | +$2.03M |
|
|
3
United Therapeutics
UTHR
$13.8B
| $110M | 5.94% | 862,295 +295,369 | +52% | +$37.8M |
|
4
Puma Biotechnology
PBYI
$254M
| $106M | 5.69% | 2,303,455 +214,338 | +10% | +$9.83M |
|
5
Vanda Pharmaceuticals
VNDA
$279M
| $102M | 5.49% | 4,443,759 -165,284 | -4% | -$3.79M |
|
|
SPPI
6
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $97.9M | 5.27% | 5,829,878 -1,133,878 | -16% | -$19M |
|
|
NVRO
7
DELISTED
NEVRO CORP.
NVRO
| $82.4M | 4.44% | 1,446,333 +503,263 | +53% | +$28.7M |
|
8
Karyopharm Therapeutics
KPTI
$61.7M
| $82.2M | 4.43% | 4,827,078 +60,000 | +1% | +$1.02M |
|
|
AMRN
9
Amarin Corp
AMRN
$311M
| $80.8M | 4.35% | 4,968,663 | – | – |
|
|
NUVA
10
DELISTED
NuVasive, Inc.
NUVA
| $77.3M | 4.16% | 1,089,523 -10,000 | -0.9% | -$710K |
|
|
11
Myriad Genetics
MYGN
$593M
| $75.7M | 4.08% | +1,646,330 | New | +$75.7M |
|
12
Pacific Biosciences
PACB
$393M
| $73.1M | 3.94% | 13,512,958 +936,956 | +7% | +$5.07M |
|
|
LMNX
13
DELISTED
Luminex Corp
LMNX
| $71.8M | 3.87% | 2,369,008 +928,882 | +65% | +$28.2M |
|
14
UroGen Pharma
URGN
$900M
| $71.6M | 3.85% | 1,515,422 +27,931 | +2% | +$1.32M |
|
15
Corcept Therapeutics
CORT
$7.35B
| $70.6M | 3.8% | 5,038,874 +410,457 | +9% | +$5.75M |
|
16
Exelixis
EXEL
$10.1B
| $68.7M | 3.7% | 3,879,050 +669,850 | +21% | +$11.9M |
|
17
Vericel Corp
VCEL
$1.83B
| $59M | 3.18% | 4,168,092 +560,000 | +16% | +$7.92M |
|
|
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
| $45.6M | 2.46% | 2,747,198 | – | – |
|
|
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $39.8M | 2.14% | 2,449,184 +110,000 | +5% | +$1.79M |
|
20
uniQure
QURE
$896M
| $38M | 2.05% | 1,045,065 | – | – |
|
|
21
Verastem
VSTM
$569M
| $37.4M | 2.01% | 5,154,224 -2,012,442 | -28% | -$14.6M |
|
22
Savara
SVRA
$567M
| $34.5M | 1.86% | 3,093,690 +382,500 | +14% | +$4.27M |
|
23
ADMA Biologics
ADMA
$4.12B
| $28.2M | 1.52% | 4,539,295 +290,061 | +7% | +$1.8M |
|
|
RARX
24
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $26.3M | 1.42% | 1,454,761 | – | – |
|
|
25
Theravance Biopharma
TBPH
$699M
| $23.9M | 1.29% | +731,909 | New | +$23.9M |
|